Atropine eye drops for myopia control in children
Key points
- Atropine eye drops have multiple uses in childhood eye care, from increasing eye examination accuracy to treatment for lazy eye, to managing eye inflammation.
- In primary-school aged children, atropine 1% can be used for the reasons described above, and atropine 0.01%, 0.025% or 0.05% can be used to slow myopia progression.
- Atropine eye drops 0.01%, 0.025% or 0.05% for myopia control have evidence for use in children aged 4 to 12 years at the start of treatment, and for up to three years.
In this article:
Atropine eye drops can be used to test and treat various eye conditions, and in low concentrations can slow myopia progression in children from age 4.
Myopia control in children
Myopia, also known as short-sightedness or near-sightedness, causes vision to become blurred in the long distance, and the need for glasses or contact lenses to see clearly.
In most cases, myopia starts in childhood, and then progressively increases up until early adulthood when it stabilizes.
'Myopia control' has become the increasingly adopted term to describe the use of treatments aimed to slow progression of myopia. These treatments can include spectacles, contact lenses or atropine eye drops. Myopia control is particularly important in children, because this is the stage in life when myopia is most likely to progress or worsen quickly. Taking action to control progression of myopia in children during this fast progression stage in their life will therefore likely achieve the most gains.
To learn more about myopia see our page What is myopia, and to learn more about myopia control read our article What is myopia control and why it's important.
What is atropine?
Atropine is used in general medicine, and also as an eye medicine or eye drop. As an eye drop, atropine 1% is used to dilate (enlarge) the pupil and stop the eye’s focusing mechanism, which can be used for testing the vision of young children, treating amblyopia (lazy eye) and also for managing some eye diseases.
The first studies using atropine eye drops to slow myopia progression in children used 1% atropine, but these had significant side effects – enlarged pupils made a child sensitive to light, and blurred their close-up vision.
Newer studies have investigated lower concentrations of 0.01% up to 0.05%, which have minimal side effects. Atropine eye drops for myopia control are used once per day, at night time.
For more background information on atropine uses in eye care and for myopia control, read All about atropine.
Atropine for myopia control in children
Atropine 1% concentration was first shown to work effectively to slow myopia progression in children aged 6-12 years, who were followed for two years.5 This concentration (strength or dose) has significant side effects of increased light sensitivity and blurred near (close up) vision. Another study on 0.1% and 0.5% found these concentrations also had significant side effects.
Atropine 0.01% to 0.05% has been shown to have minimal side effects in children who were 4 to 12 years of age at the start of treatment.
It's important to note that children on atropine treatment for myopia control will still need spectacles or contact lenses to see clearly. Atropine does not correct blurred vision from myopia, it only works to slow myopia progression.
How well does atropine work for myopia control?
A well known study from Singapore published in 2016 compared 0.01%, 0.1% and 0.5% atropine for childhood myopia control, and found that 0.01% worked similarly to the others with far less side effects.
Further analysis of that data found some flaws in assuming 0.01% works best,
Better outcomes have been found with 0.02%, 0.025% and 0.05% atropine concentrations. These have been researched in children from age 4 and up to age 14 at the start of treatment, for 2-3 years in total.
Atropine 0.02% and 0.025% have been shown to slow myopia progression by about one-third, and atropine 0.05% by about one-half, compared to children on placebo treatment.
Compared to other treatments for myopia control, atropine appears to work similarly to the best spectacle, contact lens and ortho-k options.
There are many treatment options available to slow myopia progression in children. Read more in Which is the best option for myopia control?
Atropine 0.01% has been shown to be effective when combined with ortho-k contact lens wear, boosting the short-term myopia control effect in children aged 6-11 years.
How do I know if atropine is working to slow myopia progression in my child?
There are no myopia control treatments that can promise to stop myopia progression, but they can help to slow it down.
Myopia progression can be measured either by measuring change to refraction prescription or change in the axial length of the eye, and compared to research data to determine success of a myopia control treatment.
How well a myopia treatment is working will depend on your child's age and other factors such as how the treatment is used. Read more in our article How do I know if myopia control is working? And for more detail on how axial eye length is measured see our article Measuring myopia progression using axial eye length.
Atropine safety in children
Atropine eye drops have been shown safe to use in children when used as prescribed.
The low concentrations of atropine used in myopia management have far less side effects for long term use, and have proven to be safe and effective for slowing myopia progression in children from age 4 to 14 at the start of treatment, and for up to two to three years.
As for any medication, atropine should be stored securely from children. If you do suspect your child has swallowed atropine eye drops you should immediately seek advice from the prescribing practitioner or a medical doctor.
For more detail on atropine safety, see our article All about atropine.
References
- Hou W, Norton TT, Hyman L, et al. Axial Elongation in Myopic Children and its Association With Myopia Progression in the Correction of Myopia Evaluation Trial. Eye Contact Lens. Jul 2018;44(4):248-259. [link]
The impact of myopia and high myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. 2015
[link]- Gifford KL, Richdale K, Kang P, et al. IMI - Clinical Management Guidelines Report. Invest Ophthalmol Vis Sci. Feb 2019;60(3):M184-M203. [link]
- Patel P, McLendon K, Preuss CV. Atropine. . Jan 2025. [link]
- Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology. Dec 2006;113(12):2285-91. [link]
- Yam JC, Zhang XJ, Zhang Y, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. Mar 2022;129(3):308-321. [link]
- Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. Feb 2012;119(2):347-54. [link]
- Chia A, Lu QS, Tan DTH. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. Feb 2016;123(2):391-399. [link]
- Bullimore MA, Berntsen DA. Low-Dose Atropine for Myopia Control: Considering All the Data. JAMA Ophthalmol. Mar 2018;136(3):303. [link]
- Cui C, Li X, Lyu Y, et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. Nov 2021;11(1):22267. [link]
- Brennan NA, Toubouti YM, Cheng X, et al. Efficacy in myopia control. Prog Retin Eye Res. Jul 2021;83:100923. [link]
- Tan Q, Ng AL, Cheng GP, et al. Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial. Cont Lens Anterior Eye. Feb 2023;46(1):101723. [link]
- Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. Jun 2017;135(6):624-630. [link]
- Stellpflug SJ, Cole JB, Isaacson BA, et al. Massive atropine eye drop ingestion treated with high-dose physostigmine to avoid intubation. West J Emerg Med. Feb 2012;13(1):77-9. [link]